

**MELANOMA BRIDGE**  
**Naples – Royal Continental Hotel**  
**December 5<sup>th</sup> - 7<sup>th</sup> 2019**

**SCIENTIFIC COORDINATOR**

**Paolo A. Ascierto** - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy

**SCIENTIFIC RATIONAL**

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

Latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling, in the two sessions focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies, respectively.

Conclusions will be drawn after the “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- local or systemic treatment?
- Do we really need to treat stage IIIA patients with adjuvant?
- What time is better to change treatment: progression disease or stable disease?
- Adoptive cell therapy before or in combination with check point inhibitors?

---

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012  
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la  
Formazione Continua in Sanità. Certificazione CSQA n. 23887

- Can we stop the treatment on while response?

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma and, based on the increasing success of “Melanoma Bridge” events over the years since 2011, a panel of international faculty will join the congress that will be held in December 2019.

Presidents of the event are Paolo A. Ascierto (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA) and Corrado Caracò Ascierto (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

### PRELIMINARY SCIENTIFIC PROGRAM

*\*Invited/to be invited faculty*

*\*\*Not included on CME accredited program*

#### December 5<sup>th</sup>, 2019 - Thursday

17:30 18:30 Registration\*\*

#### Melanoma Bridge Opening Session

18:30 18:50 Lecture\*\*, *Magdalena Thurin*

18:50 19:10 The struggle to understand failures and successes using immunotherapy in the treatment of cancer\*\*, *Giuseppe Masucci*

19:10 19:20 Advocacy’s Role in Educating Patients and Health Care Providers\*\*, *Valerie Guild*

#### December 6<sup>th</sup>, 2019 - Friday

09:00 9:10 Introduction and objectives, *Paolo A. Ascierto*

#### SESSION - Melanoma as a model system

**Chairpersons:** *Giuseppe Masucci, Nicola Normanno*

09:10 09:30 Harnessing the gut microbiome to optimize cancer therapy, *Laurence Zitvogel*

09:30 09:50 The unsolved issues in treatment of melanoma in the adjuvant setting, *Iman Osman*

09:50 10:10 Emerging targets in the tumor microenvironment to improve radiotherapy and immunotherapy combinations, *Sandra Demaria*

10:10 10:30 Immunotherapy-Induced Anti-Cancer Responses to the Spectrum of “Cancer Antigens” and Immune Contraction, *Bernard A. Fox*

10:30 10:50 The role of Melanoma Derived Exosome in modifying the tumor microenvironment, *Marc Ernstoff*

10:50 11:05 Break\*\*

11:05 11:25 Title to be defined, *Soldano Ferrone*

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



- 11:25 11:45 The model system for understanding checkpoint inhibitor resistance in cancer, *Georgina Long*
- 11:45 11:55 Discussion
- 11:55 12:40 Oral Communications (three slots of 15' each)
- 12:40 13:40 Symposium – TARGET THERAPY – *Paolo A. Ascierto, TBD\**
- 13:40 14:25 Lunch\*\*

### **SESSION - Mechanisms of resistance and drivers of response**

**Chairpersons:** *Giuseppe Palmieri, Gerardo Botti*

- 14:25 15:25 Symposium – ADJUVANT – *Paolo A. Ascierto, M. Mandalà*
- 15:25 15:45 Translational research in the metastatic melanoma: recent results, *Reinhard Dummer*
- 15:45 16:05 Intrinsic Tumor Genomic and Metabolic Factors Leading to Immunoresistance, *Patrick Hwu*
- 16:05 16:25 Strategies to overcome resistance to the combination of MAPK and anti-PD-1 inhibitors, *Roger Lo*
- 16:25 16:40 Break\*\*
- 16:40 17:00 Tumor mutation burden and liquid biopsies: helpful for treatment decisions?, *Claus Garbe*
- 17:00 17:20 Primary and secondary mechanisms of immunotherapy resistance, *Thomas Gajewski*
- 17:20 17:40 Next target for Immune checkpoint Blockade, *Hassane Zarour*
- 17:40 18:00 Title to be defined, *TBD\**
- 18:00 18:10 Discussion
- 18:10 18:55 Oral Communications (three slots of 15' each)
- 18:55 19:05 Discussion

### **December 7<sup>th</sup>, 2019 - Saturday**

#### **SESSION - Emergent strategies**

**Chairpersons:** *Bart Neyns, Alexander Eggermont*

- 09:00 09:20 Adjuvant Therapy for High-risk melanoma – Current Status, *Sanjiv Agarwala*
- 09:20 09:40 Neoadjuvant Immunotherapy – the pathway to therapy personalization, *Christian Blank*
- 09:40 10:00 What combinations are really worth it? *Michael Postow*
- 10:00 10:20 Transcriptional analysis of survival and T cell-inflammation nominates novel therapeutic targets, *Jason Luke*
- 10:20 10:35 Break\*\*
- 10:35 10:55 Il futuro: senza tentazioni, senza onore, *Omid Hamid*
- 10:55 11:15 Novel circulating biomarkers in melanoma, *Ryan Sullivan*

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012  
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la  
Formazione Continua in Sanità. Certificazione CSQA n. 23887



- 11:15 11:30 Discussion  
 11:30 12:15 Oral Communications (three slots of 15' each)  
 12:15 13:15 Symposium – *Paolo A. Ascierto, Georgina Long\**  
 13:15 14:00 Lunch\*\*

### Session Great Debate

**Chairpersons:** **Paolo A. Ascierto, Corrado Caracò**

- 14:00 14:30 Local vs systemic treatment  
*Sanjiv Agawarla vs Olivier Michielin*
- 14:30 14:40 Discussion
- 14:40 15:10 Do we really need to treat stage IIIA patients with adjuvant: Yes or Not?  
*Alexander Eggermont vs Jeffrey Gershenwald*
- 15:10 15:20 Discussion
- 15:20 15:50 What time is better to change treatment: progression disease or stable disease?  
*Michael Postow vs Omid Hamid*
- 15:50 16:00 Discussion
- 16:00 16:30 Adoptive cell therapy before or in combination with check point inhibitors?  
*Hassane Zarour vs Igor Puzanov*
- 16:30 16:40 Discussion
- 16:40 17:10 Can we stop the treatment on while response: Yes or Not?  
*Claus Garbe\* vs Omid Hamid\**
- 17:10 17:20 Discussion
- 17:20 17:35 Conclusions, *Paolo A. Ascierto, Corrado Caracò, Igor Puzanov*

### PRESIDENCY

**Paolo A. Ascierto** - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy

**Corrado Caracò** - Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Igor Puzanov** - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA

---

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012  
 Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la  
 Formazione Continua in Sanità. Certificazione CSQA n. 23887



## SCIENTIFIC BOARD

**Sanjiv S. Agarwala** - Professor & Chief, Haematology & Oncology, St Luke's Cancer Center & Temple University, Bethlehem, Pennsylvania, US

**Paolo A. Ascierto** - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, "Fondazione G. Pascale", Naples, Italy

**Carlo Bifulco** - Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

**Lisa H. Butterfield** - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US

**Corrado Caracò** - Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Sandra Demaria** - Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US

**Reinhard Dummer** - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox** - Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Jerome Galon** - Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Claus Garbe** - University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany

**Omid Hamid** - Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, USA

**Giuseppe Masucci** - Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

**Giuseppe Palmieri** - President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael Postow** - Memorial Sloane Kettering Cancer Center, New York City, New York, USA

**Igor Puzanov** - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA

**Magdalena Thurin** - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, USA

**Tara Withington** - Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, USA

## INVITED FACULTY

**Sanjiv S. Agarwala** - Professor & Chief, Haematology & Oncology, St Luke's Cancer Center & Temple University, Bethlehem, Pennsylvania, US

**Paolo A. Ascierto** - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, "Fondazione G. Pascale", Naples, Italy

---

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



**Christian Blank** – Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

**Gerardo Botti** - Scientific Director National Cancer Institute “Fondazione G. Pascale” Naples, Italy

**Corrado Caracò** - Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Sandra Demaria** - Professor of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medical College, New York City, New York, USA

**Reinhard Dummer** - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Alexander Eggermont** - Professor of Oncological Surgery and General Director, Institut Gustave Roussy Villejuif, Paris-Sud, France

**Marc Ernstoff** – Professor, Department of Medicine, Katherine Anne Gioia Chair, Senior VP for Clinical Investigation, Roswell, Park Comprehensive Cancer Center and Professor of Medicine. Chief, Hematology & Oncology Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University, Buffalo, New York, US

**Soldano Ferrone** - Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, US

**Bernard A. Fox** - Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Thomas Gajewski** - Oncology and Immunology Professor, Department of Pathology and Department of Medicine (Section of Haematology/Oncology) - University of Chicago (Microbiome Center), Chicago, Illinois, US

**Claus Garbe** - University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany

**Jeffrey Gershenwald** – Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, US

**Valerie Guild** - President at AIM at Melanoma, San Francisco Bay Area, California, US

**Omid Hamid** - Director Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, Los Angeles, California, US

**Patrick Hwu** - Department of Melanoma Medical Oncology, Division of Cancer Medicine, Anderson Cancer Center, Houston, Texas, US

**Roger Lo** - Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California, US

**Georgina Long** - Conjoint Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, Australia

**Jason Luke** - Assistant Professor of Medicine University of Chicago, Chicago, Illinois, US

**Giuseppe Masucci** - Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

**Olivier Michielin** – Personalised Analytical Oncology Division Director, Oncology Department UNIL—CHUV, Lausanne, Suisse

---

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012  
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la  
Formazione Continua in Sanità. Certificazione CSQA n. 23887



**Bart Neyns** - Head of division, Medical Oncology, Universitair Ziekenhuis, Brussel, Belgium

**Nicola Normanno** - Cellular Biology and Biotherapy Unit, National Cancer Institute, "Fondazione G. Pascale", Naples, Italy

**Adekunle Odunsi** - Cancer Center Deputy Director, The M. Steven Piver Professor and Chair, Department of Gynaecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, US

**Iman Osman** - Associate Dean for Translation Research and Director of the Melanoma Program, New York University Langone, Medical School, New York City, New York, US

**Giuseppe Palmieri** - President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael Postow** - Memorial Sloane Kettering Cancer Center, New York City, New York, USA

**Igor Puzanov** - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, US

**Ryan Sullivan** - Hematology-Oncology Dept, Massachusetts General Hospital, Boston, Massachusetts, US

**Magdalena Thurin** - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, US

**Hassane Zarour** - Professor of Medicine, Immunology and Dermatology, Co-Leader, Melanoma Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania, US

**Laurence Zitvogel** - Research Director, Institut Gustave Roussy, Villejuif, Paris-Sud,

---

**3P Solution S.r.l.** a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012  
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la  
Formazione Continua in Sanità. Certificazione CSQA n. 23887

